MEQSEL contains Trametinib, which is a targeted cancer medicine. It belongs to a group of drugs called MEK inhibitors. It is mainly used in cancers that have a gene change called BRAF mutation, often together with another medicine (dabrafenib).

Mechanism
Trametinib blocks a protein called MEK, which is part of the MAPK/ERK pathway. This pathway helps cancer cells grow and survive, especially when the BRAF gene is mutated. By blocking MEK, Trametinib slows down or stops the growth of cancer cells.

Uses

• Melanoma (skin cancer) with BRAF mutation

• Non-small cell lung cancer (NSCLC) with BRAF mutation

• Thyroid cancer with BRAF mutation

• Usually given in combination with Dabrafenib for better results

  Adverse Effects
  Common side effects:

  • Fever

  • Tiredness, weakness

  • Diarrhea

  • Rash, skin dryness, acne-like reaction

  • Nausea, vomiting, loss of appetite

  • Swelling in legs or arms